Semaglutide vs Tirzepatide: Which Weight Loss Drug Actually Works Better?

How Each Drug Works in Your Body

Semaglutide mimics a hormone called GLP-1—glucagon-like peptide 1. Your gut releases GLP-1 naturally after you eat. It signals your pancreas to release insulin, tells your brain you're full, and slows how fast food leaves your stomach. Semaglutide does all of that at a much higher intensity than your natural hormones can. The brand names are Ozempic (approved for type 2 diabetes) and Wegovy (approved specifically for chronic weight management).

Tirzepatide does something a bit different. It mimics two hormones—GLP-1 and another one called GIP (glucose-dependent insulinotropic polypeptide). Think of it as pulling two levers instead of one. GIP works partly in fat tissue and may amplify how efficiently the GLP-1 pathway drives weight loss. Brand names are Mounjaro (diabetes) and Zepbound (weight management). Same molecule, different FDA approvals.

That dual action is the core reason researchers expected tirzepatide to outperform semaglutide—and in most head-to-head comparisons, it does. But 'outperform' is relative. Both drugs produce meaningful weight loss in the majority of people who take them and tolerate them.

What the Clinical Trials Actually Show

The SURMOUNT-1 trial tested tirzepatide in people with obesity. At the highest dose (15 mg weekly), average body weight dropped about 20.9% over 72 weeks. That's roughly 48 pounds for a 230-pound person. The STEP 1 trial for semaglutide showed around 14.9% weight loss over 68 weeks at the 2.4 mg weekly dose—about 34 pounds for that same starting weight. Both are impressive. The gap between them is real, though.

A 2023 observational study published in JAMA Internal Medicine looked at real-world patients switching from semaglutide to tirzepatide or staying on semaglutide. Those who switched lost more weight. That's not a randomized controlled trial, so take it with some caution, but it lines up with what the individual trials suggest.

Here's the honest caveat: about 15% of people on either drug are 'non-responders'—they see minimal weight loss no matter the dose. No one can predict in advance who that will be. Genetics, gut microbiome, baseline insulin resistance, and other factors all play roles we don't fully understand yet.

• Tirzepatide 15 mg: ~20-21% average body weight loss in SURMOUNT-1
• Semaglutide 2.4 mg: ~15% average body weight loss in STEP 1
• Both outperform older obesity drugs by a wide margin
• Neither is a substitute for dietary change—they work best together with it
• Trial durations were roughly 68-72 weeks, so long-term data beyond that is still emerging

Side Effects: More Similar Than Different

Both drugs cause nausea, vomiting, constipation, and diarrhea—especially in the first few weeks as your dose ramps up. This is the main reason people stop taking them. Starting at a low dose and increasing slowly (over months, not weeks) dramatically cuts how bad those GI symptoms get. Your prescriber should walk you through a titration schedule.

Rare but serious risks exist for both. There's a theoretical concern about thyroid C-cell tumors based on animal studies—neither drug should be used if you have a personal or family history of medullary thyroid carcinoma or a condition called MEN2. Both carry a small risk of pancreatitis. If you get severe, persistent abdominal pain that radiates to your back, stop the medication and go to the ER. That's not a side effect to wait out.

One side effect getting more attention lately is 'muscle loss.' When you lose weight rapidly, some of it is lean mass, not just fat. Resistance training and adequate protein intake—think 1.2 to 1.6 grams of protein per kilogram of body weight daily—help protect muscle while you're losing. This applies to both drugs equally.

Cost and Insurance: The Painful Reality

Let's not sugarcoat this. List price for Wegovy runs around $1,350 per month. Zepbound is in a similar range, around $1,060 to $1,350 depending on dose. Without insurance, that's a serious financial burden for most families. Insurance coverage is inconsistent and often requires prior authorization, step therapy (meaning you have to try and fail other treatments first), or a documented BMI threshold.

Medicare Part D covers Zepbound for weight loss as of 2024 for certain beneficiaries, which is a shift from older policy. Medicaid coverage varies wildly by state. Both Novo Nordisk and Eli Lilly offer savings cards that can bring out-of-pocket costs down significantly for commercially insured patients—but those cards don't work if you're on Medicare or Medicaid. It's worth calling the manufacturer's patient assistance line directly if cost is a barrier.

Compounded versions of both drugs surged when they were on FDA shortage lists. As of mid-2024, FDA declared the shortage over for both and began taking action against compounders. This is a fast-moving regulatory area. If someone is offering you a steep discount on 'semaglutide,' ask a lot of questions about where it came from and who's prescribing it.

Which One Should You Actually Choose?

If efficacy alone were the only variable, the data tilts toward tirzepatide. More weight loss, on average, with a broadly similar side effect profile. But you don't make medication choices in a vacuum. Your insurance might cover one and not the other. You might have a contraindication to one. You might have already tried semaglutide and tolerated it well—or not at all.

People with type 2 diabetes often get steered toward one or the other for glucose control reasons. Both lower blood sugar, but tirzepatide tends to produce larger A1C reductions. If diabetes management is your primary goal and weight loss is secondary, that distinction matters more. If you have heart disease, semaglutide has longer-term cardiovascular outcome data (the SELECT trial showed a 20% reduction in major cardiovascular events). Tirzepatide's cardiovascular trial (SURMOUNT-MMO) is ongoing.

This is genuinely a conversation to have with your doctor or an obesity medicine specialist—not a decision to make based on what your neighbor lost. Bring your insurance card, your medical history, and these questions: Which drug is covered? What dose would we start at? How do we measure whether it's working? What's the plan if I can't tolerate the side effects?

• Ask your insurer for a formulary exception if your preferred drug isn't covered
• Obesity medicine specialists often have more experience managing these medications than general practitioners
• Switching drugs is an option—some patients do better after moving from one to the other
• Neither drug should be stopped abruptly without a plan; weight often returns after discontinuation

The Weight Regain Problem Nobody Likes to Talk About

Both drugs work while you're on them. Stop taking either one, and a significant portion of the weight typically comes back within a year—sometimes most of it. The STEP 4 trial for semaglutide showed participants regained about two-thirds of their lost weight within a year of stopping. Tirzepatide data shows a similar pattern. This doesn't mean the drugs have failed. It means obesity is a chronic disease that, for many people, requires long-term management.

That reframing is uncomfortable for a lot of patients—and for payers who don't want to fund lifelong prescriptions. But compare it to how we treat high blood pressure or high cholesterol. Nobody expects you to take a blood pressure pill for two years and then never need it again. The same logic applies here, even if society hasn't fully caught up to that idea yet.

If you're considering either medication, go in with realistic expectations: this is likely a long commitment, not a short-term fix. Having a plan for what happens if you need to stop—financially, medically, behaviorally—is worth discussing upfront.

Common questions